[1]吴嘉旭,胡明超,王强,等.NDC1基因在肝癌中的诊断及预后价值的生物信息学分析[J].福建医药杂志,2023,45(01):7-12.
　WU Jiaxu,HU Mingchao,WANG Qiang,et al.Bioinformatics analysis of the diagnostic and prognostic value of NDC1 gene in liver hepatocellular carcinoma[J].FUJIAN MEDICAL JOURNAL,2023,45(01):7-12.
点击复制

NDC1基因在肝癌中的诊断及预后价值的生物信息学分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年01期
页码:
7-12
栏目:
临床研究
出版日期:
2023-02-15

文章信息/Info

Title:
Bioinformatics analysis of the diagnostic and prognostic value of NDC1 gene in liver hepatocellular carcinoma
文章编号:
1002-2600(2023)01-0007-06
作者:
吴嘉旭; 胡明超; 王强; 俞文渊; 许华1
南京医科大学附属江苏盛泽医院普外科 南京医科大学康达学院盛泽临床医学院(苏州 215228)
Author(s):
WU Jiaxu; HU Mingchao; WANG Qiang; YU Wenyuan; XU HUA
Shengze School of Clinical Medicine, Kangda College of Nanjing Medical University, Department of General Surgery, the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, Jiangsu 215228, China
关键词:
肝癌;  NDC1基因;  预后;  生物信息学
Keywords:
liver hepatocellular carcinoma;  NDC1 gene;  prognosis;  bioinformatics
分类号:
R735.7
文献标志码:
B
摘要:
目的 基于生物信息学的方法研究NDC1基因用于肝癌的诊断及预后评估方面的作用。方法 以TCGA数据库和GTEx为发现数据库,使用软件下载所有肝癌患者以及健康人的level 3 HTSeq-TPM格式的RNA测序结果,绘制箱式图及点图用于统计NDC1基因在肝癌组织及正常组织中的差异化表达情况,并使用GEPIA作为验证数据库进行佐证。绘制受试者曲线来评估NDC1基因用于诊断肝癌的效能。根据NDC1基因表达量的中位数将患者区分为NDC1高表达和低表达两组,研究肝癌患者的临床病理特征以及预后情况和NDC1基因表达的关系。绘制生存曲线,探究NDC1基因的高低表达与LIHC患者的生存情况的关系。结果 肝癌患者的NDC1的表达量为2.16(1.746～2.64),明显大于正常组织中的1.449(1.263～1.644),差异有统计学意义(P<0.05); 同样的,在55对配对组织中,NDC1基因在肝癌组织中的表达量3.47(3.028～3.749)也明显高于对应的癌旁正常组织中NDC1的表达量2.426(2.278～2.611),差异有统计学意义(P<0.05)。受试者曲线的结果显示了NDC1用于诊断肝癌有着较高的敏感性[曲线下面积=0.843,95%置信区间为(0.809,0.877)]; 在针对NDC1基因表达和肝癌患者临床病理特征以及预后的关系研究中发现NDC1高表达的肝癌患者相比NDC1低表达患者有着更晚的T分期(P<0.05)和病理分期(P<0.05); 此外,NDC1基因高表达的肝癌患者总体生存期也短于NDC1基因低表达的患者。结论 NDC1基因有潜力成为用于肝癌诊断和预后评估的新型生物学标志物。
Abstract:
Objective To investigate the role of the NDC1 gene for the diagnosis and prognostic evaluation of liver hepatocellular carcinoma(LIHC)based on bioinformatics approach.Methods The TCGA and GTEx database were used as the discovery databases and RNA sequencing results in level 3 HTSeq-TPM format from all LIHC patients as well as healthy individuals were downloaded using R software,and box plots and dot plots were peformed for analyzing the differential expression of NDC1 gene in LIHC tissues and normal tissues,and GEPIA was used as a validation database for corroboration.Secondly,Receiver Operating Characteristic(ROC)curve was drawn to assess the efficacy of the NDC1 gene for the diagnosis of LIHC.Patients were divided into low NDC1 expression group and high NDC1 expression group based on the median NDC1 gene expression,and the relationship between clinicopathological characteristics and prognosis of patients with LIHC and NDC1 gene expression was investigated.The relationship between the high and low expression of NDC1 gene was explored by drawing the survival curve of LIHC patients.Results The expression of NDC1 in patients with LIHC was 2.16(1.746-2.64),which was significantly higher than that of 1.449(1.263-1.644)in normal tissues,and the difference was statistically significant(P<0.05); similarly,in 55 paired tissues,the expression of NDC1 gene in LIHC tissues was 3.47(3.028-3.749),which was also significantly higher than that in the adjacent normal tissues 2.426(2.278-2.611),with statistically significant difference(P<0.05).The results of ROC curves showed a high sensitivity of NDC1 for the diagnosis of LIHC[area under curve=0.843,95% confidence interval(0.809,0.877)]; In the study of the relationship between NDC1 gene expression and the clinicopathological characteristics and prognosis of LIHC patients,we found that the LIHC patients with high NDC1 expression had more advanced T-stage and pathological stage compared with those with low NDC1 expression(P<0.05); moreover,the overall survival of LIHC patients with high NDC1 gene expression was shorter than that of patients with low NDC1 gene expression.Conclusion The NDC1 gene has the potential to be a novel biological marker for the diagnosis and prognostic evaluation of LIHC.

参考文献/References:

[1] Akinyemiju T,Abera S,Ahmed M,et al.The Burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,regional,and national level:results from the global burden of disease study 2015[J].JAMA Oncol,2017,3(12):1683-1691.
[2] Agopian V G,Harlander-Locke M P,Markovic D,et al.Evaluation of patients with hepatocellular carcinomas that do not produce α-fetoprotein[J].JAMA Surg,2017,152(1):55-64.
[3] Lou J T,Zhang L F,Lv S G,et al.Biomarkers for Hepatocellular Carcinoma[J].Biomark Cancer,2017,9:1-9.
[4] Zhu A X,Kang Y K,Yen C J,et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(2):282-296.
[5] Mehta N,Heimbach J,Harnois D M,et al.Validation of a risk estimation of tumor recurrence after transplant(retreat)score for hepatocellular carcinoma recurrence after liver transplant[J].JAMA Oncol,2017,3(4):493-500.
[6] Zheng S Y,Cherniack A D,Dewal N,et al.Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma[J].Cancer Cell,2016,30(2):363.
[7] Cancer Genome Atlas Network.Comprehensive molecular characterization of human colon and rectal cancer[J].Nature,2012,487(7407):330-337.
[8] Song P P,Tang Q,Feng X B,et al.Biomarkers:evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma[J].Scand J Clin Lab Invest Suppl,2016,245:S70-76.
[9] De Stefano F,Chacon E,Turcios L L,et al.Novel biomar-kers in hepatocellular carcinoma[J].Dig Liver Dis,2018,50(11):1115-1123.
[10] Ghouri Y A,Mian I,Rowe J H.Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis[J].J Carcinog,2017,16:1.
[11] Yamazumi Y,Kamiya A,Nishida A,et al.The transmembrane nucleoporin NDC1 is required for targeting of ALADIN to nuclear pore complexes[J].Biochem Biophys Res Commun,2009,389(1):100-104.
[12] Lai T H,Wu Y Y,Wang Y Y,et al.SEPT12-NDC1 complexes are required for mammalian spermiogenesis[J].Int J Mol Sci,2016,17(11):1911.
[13] Qiao W L,Han Y D,Jin W,et al.Overexpression and biological function of TMEM48 in non-small cell lung carcinoma[J].Tumour Biol,2016,37(2):2575-2586.
[14] Liu M,Yuan R,Liu S F,et al.NDC1 is a prognostic biomarker and associated with immune infiltrates in colon cancer[J].Int J Gen Med,2021,14:8811-8817.

相似文献/References:

[1]陈扬,萨本仲,张韬,等.双氢青蒿素通过mTOR信号通路对肝癌Hep-G2细胞凋亡的影响[J].福建医药杂志,2022,44(04):121.
[2]李业森.68Ga标记TMTP1探针在肝癌肿瘤模型中的microPET/CT显像研究[J].福建医药杂志,2022,44(05):122.
　Li Yesen.Study on microPET/CT imaging of 68GA-labeled TMTP1 probe in HCC tumor model[J].FUJIAN MEDICAL JOURNAL,2022,44(01):122.

备注/Memo

备注/Memo:
基金项目:苏州市医学重点学科(SZXK202126); 南京医科大学康达学院科研发展基金(KD2022KYJJZD015)
1 通信作者
更新日期/Last Update: 2023-02-15